Vanguard Investments Australia
TXG icon

Vanguard Investments Australia’s 10x Genomics TXG Stock Holding History

Vanguard Investments Australia’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.04M Hold
27,201
– – ﹤0.01% 1255
2026
Q1 		$577K Buy
+27,201
New +$544K ﹤0.01% 1505

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
QCM
Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Investments Australia's TXG Position: Q2 2026 in Review

Vanguard Investments Australia held its 10x Genomics (TXG) position steady in Q2 2026 at 27,201 shares worth $1.04M. The position accounts for ﹤0.01% of the portfolio, ranked #1255.

Vanguard Investments Australia first reported a position in TXG in Q1 2026 and has held it in 2 quarters since. 390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

  • Vanguard Investments Australia held 27,201 shares of 10x Genomics worth $1.04M as of Q2 2026.
  • Vanguard Investments Australia left its 10x Genomics share count unchanged in Q2 2026.
  • 10x Genomics made up ﹤0.01% of Vanguard Investments Australia's portfolio in Q2 2026, its #1255 holding.
  • Vanguard Investments Australia first reported a position in 10x Genomics in Q1 2026 and has held it in 2 quarters since.
  • 390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Vanguard Investments Australia's 13F filing for Q2 2026, filed 13 Aug 2026.